



BCIL Biotech Consortium India Limited

THERAPEUTIC COMPOSITION FOR QUICK HEALING OF WOUNDS AND ASSOCIATED INFLAMMATION

TECHNOLOGY AVAILABLE FOR TRANSFER

UNMET NEED / OPPORTUNITIES

- Biologics and immune selective anti-inflammatory derivatives are the promising drugs classes that will play the main role in the market
- Global Market for **Anti-inflammatory Therapeutics is USD 97.8 Billion** for 2020 Market forecast to grow at **CAGR of 4.8%**
- Global Market for **Wound Care Market USD 19.8 Billion** for 2021 Market forecast to grow at **CAGR of 7.6%**
- Commercially available Biologic Anti-inflammatory drugs are used essentially for Arthritis patients and can be categorized in in three such as a. TNF inhibitor, b. B-cell inhibitors, and c. Interleukin-1 blockers.
- The present technology as a product, focuses on a broad-spectrum inflammatory disease and targets inhibition of Mast cells as they are first line of inflammatory response

TECHNOLOGY

- The **recombinant rPPE2 protein sequence therapeutic composition** for **Scar free** wound healing and associated inflammation
- Invention provides a **Formulation** (Gel/Injection forms) and its **method of preparation**
- The technology inhibits **stem cell factor (SCF)** which is responsible for **mast cell** development and activation
- The rPPE2 is **short sequence** for easy cellular delivery
- rPPE2 protein comprising **SEQ ID NO: 1** (sequence of 556 amino acids) is **NOVEL** and associated with scar free wound healing

INTELLECTUAL PROPERTY


- Patent Published in India and USA

UNIQUE SELLING PROPOSITION

- Novel protein-based **wound and associated inflammation healing** formulation
- **Scar free** wound healing (Gel: cosmetic Industry)
- **Short protein sequence** for an easy delivery
- Effective against **Excisional wound and local inflammation** tissue injury
- Drug is **Long acting (16- 21 days)**
- Dosage reduced to almost **one third of the standard drugs**
- **Single injectable dose** can be developed in other forms such as capsules, pills, tablet, spray or ointment

STAGE OF DEVELOPMENT

- **TRL-4 Proof of concept** established and validated at laboratory scale using *In-Vitro* and *In-Vivo* Animal models
- **Gel composition/Injection** (efficacy, purity, safety validated)
- Comparative experiment using Diclofenac sodium for injection formulation and EGF (REGEN-D,) for Dermal Gel formulation indicated improved efficacy



LICENSING OPPORTUNITY

TTO@BCIL is looking for a suitable industrial partner for the Technology development and commercialization

CONTACT: BIOTECH CONSORTIUM INDIA LIMITED

Dr. Shiv Kant Shukla, (Dy. General Manager)

V Floor, Anuvrat Bhawan, 210, Deen Dayal Upadhyaya Marg, New Delhi:110002

Tel.: +91-11-23219058

Email: shuklashivkant@biotech.co.in or tto.bcil@biotech.co.in

Website: www.biotech.co.in